HSA
RIGL icon

Hussman Strategic Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Hussman Strategic Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,500
Closed -$2.25M – 324
2025
Q4 		$2.25M Buy
+52,500
New +$1.98M 0.54% 70
2023
Q2 		– Sell
-15,600
Closed -$206K – 335
2023
Q1 		$206K Hold
15,600
– – 0.03% 294
2022
Q4 		$234K Hold
15,600
– – 0.04% 278
2022
Q3 		$184K Hold
15,600
– – 0.03% 276
2022
Q2 		$176K Hold
15,600
– – 0.03% 289
2022
Q1 		$466K Hold
15,600
– – 0.09% 262
2021
Q4 		$413K Buy
+15,600
New +$471K 0.09% 262

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hussman Strategic Advisors's RIGL Position: Q1 2026 in Review

Hussman Strategic Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 52,500 shares — an estimated $2.25M sold.

Hussman Strategic Advisors first reported a position in RIGL in Q4 2021 and held it in 7 quarters. The position peaked at $2.25M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Hussman Strategic Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 52,500 Rigel Pharmaceuticals shares in Q1 2026, an estimated $2.25M.
  • Hussman Strategic Advisors first reported a position in Rigel Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Hussman Strategic Advisors's Rigel Pharmaceuticals position peaked at $2.25M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.